Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00135785 · ClinicalTrials.gov registry record · Phase 2

Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2

A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 2
Development phase
73
Enrollment target

NCT00135785 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 73 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00135785, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 2
Development phase
73 participants
Enrollment target

Study Summary

Methamphetamine is an addictive stimulant drug that strongly activates certain parts of the brain. The purpose of this study is to determine the effectiveness of bupropion in combination with behavioral therapy for the treatment of methamphetamine addiction.

Interventions

  • DRUG Placebo
  • DRUG Bupropion

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2005-10
Est. Completion 2007-05
Phase Phase 2

What the Registry Record Tells You About NCT00135785

The ClinicalTrials.gov registry entry for NCT00135785 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00135785 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00135785 about?

NCT00135785 is a clinical study titled "Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2". Methamphetamine is an addictive stimulant drug that strongly activates certain parts of the brain. The purpose of this study is to determine the effectiveness of bupropion in combination with behavioral therapy for the treatment of methamphetamine addiction.

What is the current status of trial NCT00135785?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2005-10. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00135785?

The interventions under investigation include: Placebo (DRUG), Bupropion (DRUG).

Who is sponsoring clinical trial NCT00135785?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.